Why is Zim Laboratories falling/rising?

As of 17-Sep, Zim Laboratories Ltd is currently priced at 75.90, reflecting an increase of 0.72 or 0.96%. The stock has shown a performance today that outperformed its sector by 0.92%. However, it is important to note that while the stock is higher than its 5-day and 20-day moving averages, it remains below its 50-day, 100-day, and 200-day moving averages. Over the past week, the stock has gained 1.50%, but it has underperformed the benchmark Sensex over the last month with a return of only 0.53% compared to the Sensex's 2.60%. The stock has also faced a significant decline in investor participation, with delivery volume falling by 35.06% against the 5-day average. Despite an attractive valuation indicated by a 1.3 enterprise value to capital employed and trading at a discount compared to peers, the company has reported a substantial profit decline of 47.6% over the past year, contributing to a year-to-date return of -29.07%.
In the broader market context, Zim Laboratories has consistently underperformed against the benchmark over the last three years, with a staggering decline of 70.28% compared to the Sensex's gain of 40.54%. This underperformance is compounded by weak long-term fundamentals, including a low return on capital employed (ROCE) of 7.99% and negative results reported for the last five consecutive quarters. The company's net sales have also decreased by 12.3%, indicating ongoing challenges. While the stock has seen a slight uptick today, the overall trend suggests significant underlying issues that continue to affect its performance relative to the broader market.